Related Experiment Video
Updated: Jan 5, 2026
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
6.0K
Specific glioblastoma multiforme prognostic-subtype distinctions based on DNA methylation patterns.
Huihui Ma1,2, Chenggang Zhao1,2, Zhiyang Zhao1,2
1Anhui Province Key Laboratory of Medical Physics and Technology; Center of Medical Physics and Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, No. 350, Shushan Hu Road, Hefei, Anhui, 230031, China.
Cancer Gene Therapy
|October 18, 2019
Summary
DNA methylation analysis identified three Glioblastoma Multiforme (GBM) subtypes with distinct prognoses. This methylation-based model aids in understanding GBM heterogeneity and guiding clinical treatment decisions.
Area of Science:
- Oncology
- Genetics
- Epigenetics
Background:
- DNA methylation is a key regulator of gene expression and a significant factor in brain tumor development.
- Glioblastoma Multiforme (GBM) exhibits considerable molecular heterogeneity, impacting patient prognosis and treatment response.
Purpose of the Study:
- To identify distinct Glioblastoma Multiforme (GBM) prognostic subtypes based on DNA methylation patterns.
- To develop a methylation-based model for predicting GBM patient outcomes and treatment sensitivity.
Main Methods:
- Utilized DNA methylation profiles from 138 Glioblastoma Multiforme (GBM) samples in The Cancer Genome Atlas (TCGA) database.
- Applied consensus clustering on 11,637 CpG sites correlated with survival, and Weighted Gene Co-expression Network Analysis (WGCNA) to identify key methylation features.
- Validated findings using hierarchical clustering on training and test sets, and independent clinical GBM specimens.
Main Results:
- Identified three distinct GBM molecular subtypes with significantly different survival curves.
- Discovered ten feature CpG sites that effectively classified samples into high- and low-methylation groups.
- Observed a positive correlation between methylation levels and sensitivity to temozolomide/radiotherapy, and anti-migration ability in GBM cells.
Conclusions:
- The developed DNA methylation model elucidates GBM molecular subgroup heterogeneity.
- This model offers valuable insights for clinical prognosis and personalized treatment strategies in Glioblastoma Multiforme.
